As of Nov 19, 2026, 1 of 1 active firms rate AYTU a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AYTU EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.18 – $-0.09 · 2 analysts · -42% YoY
Next period, 2 analysts expect Aytu BioScience Inc to earn $-0.14 a share (range $-0.18 – $-0.09), versus $-0.23 a year earlier. Full-year consensus is $-0.36, growing to $0.15 the year after.
REVENUE · NEXT QUARTER
$15.3M
Range $15.0M – $15.7M · 2 analysts · +24% YoY
Revenue is expected to reach $15.3M (range $15.0M – $15.7M), +24.0% year-over-year. Full-year consensus is $67.9M, rising to $86.9M next year.
Top analysts covering Aytu BioScience Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AYTU.
#1
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$7.00+163.2% to target
Overall win rate
40%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #570
Buy
$15.00+463.9% to target
Overall win rate
24%
+ Follow
#3
NR
Naz Rahman
Maxim Group · Rank #578
Buy
$7.00+163.2% to target
Overall win rate
27%
+ Follow
#4
EW
Edward Woo
Ascendiant
Buy
$14.50+445.1% to target
Coverage
—
+ Follow
AYTU stock forecast FAQ
What is AYTU's average 12-month price target?+
The 1 active firms with a live target average $15.00 for Aytu BioScience Inc over the next 12 months, ranging from a $15.00 high to a $15.00 low, as of Nov 19, 2026.
Is AYTU stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover AYTU?+
1 active firms have a recognized rating on Aytu BioScience Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AYTU?+
Among analysts who currently cover AYTU, Thomas Flaten of Lake Street has the strongest overall Quantellect track record (Rank #306). Their current call is Buy with a $7.00 target.
What is Aytu BioScience Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.18 – $-0.09) across 2 analysts. Full-year EPS is projected at $-0.36, rising to $0.15 the following year.
How much revenue is Aytu BioScience Inc expected to report next quarter?+
Consensus revenue is $15.3M (range $15.0M – $15.7M). Full-year revenue is projected at $67.9M, growing to $86.9M next year.
Have analysts been upgrading or downgrading AYTU lately?+
As of Nov 19, 2026, 1 of 1 active firms rate AYTU a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AYTU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.